Evidence map›Paper›PMID 34288538›Full record

ArticleCancer medicine2021

Clinical outcomes of stereotactic magnetic resonance image-guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis.

Stephanie M Yoon, Elaine Luterstein, Fang-I Chu, Minsong Cao, James Lamb, Nzhde Agazaryan, Daniel Low, Ann Raldow, Michael L Steinberg, Percy Lee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Stephanie M YoonDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0001-5864-2522
Elaine LutersteinUniversity of California San Diego School of Medicine, San Diego, CA, USA.
Fang-I ChuDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Minsong CaoDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
James LambDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Nzhde AgazaryanDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Daniel LowDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Ann RaldowDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0001-8996-6810
Michael L SteinbergDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Percy LeeDepartment of Radiation Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeStereotactic body radiotherapy (SBRT) delivers ablative doses with excellent local control. However, implementing SBRT for abdominal and pelvic tumors has been limited by the risk for treatment-related gastrointestinal toxicity. MRI-guided radiotherapy may ameliorate these risks and increase the therapeutic ratio. We report the clinical outcomes of stereotactic MRI-guided adaptive radiotherapy (SMART) for primary and metastatic tumors in the abdomen and pelvis.

methodsFrom November 2014 to August 2017, the first 106 consecutive patients with 121 tumors in the abdomen and pelvis were treated with SMART at a single institution. Of the cohort, 41.5%, 15.1%, and 43.4% had primary, locally recurrent, and oligometastatic tumors, respectively. SMART was delivered using a tri-cobalt-60 gantry with on-board 0.35 Tesla MRI with respiratory breath-hold and daily adaptive re-planning when anatomically necessary. A median of 40Gy in five fractions was prescribed. The Common Terminology Criteria for Adverse Events v.4.03 was used to score treatment-related toxicities. Local control (LC), progression-free survival (PFS), and overall survival (OS) were estimated using Kaplan-Meier method.

resultsOf the 510 treatments, seventy-one (13.9%) were adapted. Fatigue, nausea, and pain were the most common acute toxicities. 0.9 and 0% of patients experienced acute grade three and four toxicities, respectively. 5.2 and 2.1% of patients experienced late grade three and four toxicities, respectively. After a median follow-up of 20.4 months, the 2-year LC rate was 74% on a per-lesion basis. Two-year LC was 96% for lesions that were treated with BED

conclusionsFavorable LC and PFS outcomes were observed with minimal morbidity for tumors in the abdomen and pelvis treated with SMART. Future prospective clinical trials to validate these findings are warranted.

Indexed as

AbdomenAgedHumansNeoplasm MetastasisNeoplasmsPelvisRadiosurgeryRadiotherapy, Image-GuidedRetrospective StudiesSurvival AnalysisTreatment Outcomeabdominal pelvic tumorscancer managementMR-guided radiation therapystereotactic ablative radiotherapystereotactic body radiation therapy

Identifiers

PMID34288538
PMCPMC8419771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.